Prospects of prostanoid therapy. Preliminary results

Minerva Cardioangiol. 2000 Jan-Feb;48(1-2):9-18.
[Article in English, Italian]

Abstract

Background: To evaluate the efficacy of treatment with prostaglandins (Iloprost and Alprostadil) in patients with peripheral arterial disease in whom a surgical act or a redo operation is not proposable and to set the role of these drugs in the therapy of arterial diseases.

Methods: We analyzed the results of 96 treatments in patients with peripheral arterial diseases of different etiology, treated in the Day Hospital in the Division of Vascular Surgery from the 1/1/1993 to the 30/6/1998. The efficacy of the treatment has been evaluated on the basis of the clinical picture (healing or reduction of ulcers, reduction of rest-pain, improvement of the ability to walk).

Results: We had positive results in 60% of the patients who completed the treatment, a good outcome for patients with particularly severe arterial disease. Interruptions induced by the occurrence of uncontrolled side-effects are a few (6.25%). Better results have been found in a special category of disease (arterial diseases not associated with diabetes, not very advanced clinical picture, female gender). Iloprost proved to be superior to Alprostadil.

Conclusions: Prostaglandins today represent an effective therapeutic solution to be considered. Further studies need to be done to find a category of patients who can have the best benefit from this kind of drug.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alprostadil / adverse effects
  • Alprostadil / therapeutic use*
  • Arterial Occlusive Diseases / drug therapy
  • Feasibility Studies
  • Female
  • Humans
  • Iloprost / adverse effects
  • Iloprost / therapeutic use*
  • Male
  • Middle Aged
  • Peripheral Vascular Diseases / drug therapy
  • Vasodilator Agents / adverse effects
  • Vasodilator Agents / therapeutic use*

Substances

  • Vasodilator Agents
  • Alprostadil
  • Iloprost